Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

In its third-quarter 2024 earnings report, Ginkgo Bioworks highlighted significant achievements in its strategic realignment, including signing new deals with Novo Nordisk and Merck, and making ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Hospital divestitures also shaped the for-profit health system’s finances, which included $5.1 billion in revenue.

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Operator: Greetings, and welcome to AirSculpt Technologies, Inc. Third Quarter 2024 Earnings Conference Call. At this time ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...